Cidara Therapeutics Inc
$ 221.38
0.00%
07 Jan - close price
- Market Cap 6,961,584,000 USD
- Current Price $ 221.38
- High / Low $ 221.38 / 221.38
- Stock P/E N/A
- Book Value 14.40
- EPS -11.20
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.29 %
- ROE -0.69 %
- 52 Week High 221.42
- 52 Week Low 15.22
About
Cidara Therapeutics, Inc., a biotechnology company, is focused on the discovery, development, and commercialization of new long-acting anti-infectives for the treatment and prevention of disease in the United States. The company is headquartered in San Diego, California.
Analyst Target Price
$221.50
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-07 | 2025-04-21 | 2025-03-07 | 2024-10-31 | 2024-08-13 | 2024-05-15 | 2024-03-27 | 2023-11-02 | 2023-08-03 | 2023-05-11 | 2023-03-23 |
| Reported EPS | -3.1 | -1.65 | -1.66 | -5.38 | -2.45 | -19.99 | -2.28 | -0.04 | -0.09 | -0.14 | 0.03 | -0.19 |
| Estimated EPS | -2.77 | -3.04 | -3.4725 | -3.6725 | -4.25 | -3.22 | -0.2 | -0.1 | -0.16 | -0.13 | -0.04 | -0.17 |
| Surprise | -0.33 | 1.39 | 1.8125 | -1.7075 | 1.8 | -16.77 | -2.08 | 0.06 | 0.07 | -0.01 | 0.07 | -0.02 |
| Surprise Percentage | -11.9134% | 45.7237% | 52.1958% | -46.4942% | 42.3529% | -520.8075% | -1040% | 60% | 43.75% | -7.6923% | 175% | -11.7647% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CDTX
2026-02-09 13:29:43
Merck has completed its tender offer to acquire Cidara Therapeutics by purchasing approximately 85.96% of Cidara's outstanding stock at $221.50 per share. Merck plans to finalize the acquisition through a merger, making Cidara a wholly owned subsidiary and delisting its shares from Nasdaq. This acquisition aims to strengthen Merck's respiratory portfolio, particularly with Cidara's investigational antiviral CD388, and is expected to impact Merck's 2026 R&D expenses and earnings per share.
2026-02-03 11:29:09
Merck & Co. announced strong fourth-quarter and full-year 2025 financial results, with worldwide sales reaching $16.4 billion and $65.0 billion respectively, driven by robust performance in Oncology and Animal Health, and increasing contributions from WINREVAIR and CAPVAXIVE. The company also highlighted significant pipeline advancements, including positive late-stage trial results for 18 Phase 3 trials and strategic acquisitions that augmented its portfolio. Merck further detailed its 2026 financial outlook, anticipating worldwide sales between $65.5 billion and $67.0 billion and non-GAAP EPS between $5.00 and $5.15.
2026-01-23 05:28:34
RedChip Companies congratulated its former client, Cidara Therapeutics, on its acquisition by Merck for approximately $9.2 billion. RedChip had introduced Cidara to its investor network in 2021 when its market capitalization was under $100 million. The acquisition highlights Cidara's CD388, an investigational antiviral in Phase 3 development for influenza prevention.
2026-01-11 07:10:40
RedChip Companies congratulated its former client, Cidara Therapeutics, on its approximately $9.2 billion acquisition by Merck. RedChip had introduced Cidara to its investor network in 2021 when the company was valued under $100 million. The acquisition highlights Cidara’s innovative Cloudbreak® platform and its lead compound CD388, an investigational long-acting antiviral in Phase 3 development for influenza prevention.
2026-01-11 06:28:34
Wall Street Zen has upgraded Cidara Therapeutics (NASDAQ:CDTX) to a "sell" rating, despite some other analysts maintaining "buy" or "hold" ratings, leading to a mixed sentiment and an average target price of $156.11. The company recently missed its quarterly EPS estimates, and its COO sold a significant portion of his shares. Cidara Therapeutics is a clinical-stage biotechnology company focused on anti-infectives and immunotherapies, with its lead asset rezafungin in late-stage development.
2026-01-10 19:27:14
Cidara Therapeutics has completed its acquisition by Merck Sharp & Dohme LLC, ceasing to be a publicly traded company. Merck's subsidiary acquired Cidara shares for $221.50 per common share and $15,505.00 per Series A preferred share in cash, resulting in the delisting of CDTX from Nasdaq and the termination of Cidara's public reporting obligations. The transaction was finalized on January 7, 2026, with Merck designees taking over governance.
